drugset / Trial / NCT00050609

Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying

NCT00050609

Phase 2 Completed 2 enrolled Eli Lilly and Company ICOS Corporation · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting) in diabetic patients, and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this population will also be studied.

Timeline

Start
2003-02
Primary completion
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tadalafil Small molecule 5 mg Oral
Comparator Tadalafil Small molecule 20 mg Oral

Indications